publication date: Jun. 12, 2015

Karen Knudsen Named Director of Sidney Kimmel Cancer Center at Thomas Jefferson University


KAREN KNUDSEN was named director of the Sidney Kimmel Cancer Center at Thomas Jefferson University.

Knudsen is the Hilary Koprowski Professor of Cancer Biology and Chair of Cancer Biology at Thomas Jefferson University, with joint appointments in the Departments of Urology, Radiation Oncology, and Medical Oncology.

Knudsen also served as the first Vice Provost for Thomas Jefferson University, overseeing and integrating basic and clinical research across all six schools at TJU.

Knudsen’s research interests focus on genetic alterations that lead to prostate cancer progression and resistance to therapy.

During her eight years at Jefferson, Knudsen founded the Prostate Cancer Program of Excellence at SKCC, and also directs a multi-disciplinary think tank of scientists and clinicians called the Greater Philadelphia Prostate Cancer Working Group.

Knudsen’s research on a newer chemotherapy treatment for prostate cancer, called cabazitaxel, revealed that this therapy could be useful for some patients earlier in their course of treatment. Her team also discovered a biomarker that may predict which patients would benefit from earlier treatment.

More recent studies from Knudsen’s group connected alterations in DNA repair pathways with aggressive prostate cancers.

Knudsen serves on multiple national boards and committees associated with both basic and clinical research, including several for the American Association for Cancer Research, the Endocrine Society, the American Society for Clinical Oncology, and the Prostate Cancer Foundation. She is an associate editor for Endocrine-Related Cancer, and sits … Continue reading 41-29 Karen Knudsen Named Director Of Sidney Kimmel Cancer Center at Thomas Jefferson University

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.